leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...5960616263646566676869...235236»
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  MEDITREME: Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC (clinicaltrials.gov) -  Feb 10, 2023   
    P1/2,  N=57, Completed, 
    Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Unknown status --> Completed | Trial completion date: Aug 2020 --> Jan 2023 | Trial primary completion date: Aug 2020 --> Jan 2023
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Metastases:  Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer (clinicaltrials.gov) -  Feb 8, 2023   
    P1/2,  N=0, Withdrawn, 
    No abstract available N=59 --> 0 | Trial completion date: Jan 2025 --> Jan 2023 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2024 --> Jan 2023
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Review, Journal, Metastases:  Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective. (Pubmed Central) -  Feb 7, 2023   
    The addition of durvalumab, a monoclonal antibody targeting the immune checkpoint programmed cell death ligand-1, to CisGem in the first-line treatment of advanced BTC has shown an overall survival benefit in the TOPAZ-1 trial. Given the high mortality rates associated with BTC and the life-prolonging therapeutic options now available, it is hoped that the data presented here will support updates to the clinical management of BTC in France.
  • ||||||||||  Zaltrap (ziv-aflibercept IV) / Sanofi
    Trial completion:  mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer (clinicaltrials.gov) -  Feb 6, 2023   
    P2,  N=119, Completed, 
    Given the high mortality rates associated with BTC and the life-prolonging therapeutic options now available, it is hoped that the data presented here will support updates to the clinical management of BTC in France. Active, not recruiting --> Completed
  • ||||||||||  methotrexate / Generic mfg.
    A Perilous Mistake: Methotrexate-induced Epidermal Necrosis Mimicking Stevens Johnson Syndrome (Convention Center, Ballroom Level, Room 304A) -  Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1599;    
    The patient's hypocellular bone marrow and associated pancytopenia strongly favors a diagnosis of methotrexate-included epidermal necrosis. Patient received leucovorin and G-CSF and was transferred to a burn unit for supportive care.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    Journal, Metastases:  Cases of Advanced Colorectal Cancer with Nephrotic Syndrome after FOLFIRI plus Ramucirumab Administration (Pubmed Central) -  Feb 4, 2023   
    The patient received 15 postoperative CAPOX plus bevacizumab(Bev)courses...Therefore, postoperative mFOLFOX6 plus Bev was administered for 17 courses...In both cases, marked proteinuria was observed after shifting to second-line treatment with two RAM administrations. Therefore, monitoring nephrotic syndrome development during the early RAM introduction stage is essential.
  • ||||||||||  Journal:  Long-Term Survival following Multidisciplinary Therapy for Unresectable Pancreatic Body Cancer (Pubmed Central) -  Feb 4, 2023   
    We diagnosed unresectable pancreatic cancer(T3N0M1, cStage Ⅳ)and administered 10 courses of gemcitabine(GEM)plus nab-paclitaxel(nab-PTX)therapy...Therefore, we further administered 6 courses of FOLFIRINOX therapy and 4 courses of GEM plus nab-PTX therapy, but CA19-9 was not normalized...On day 52 after surgery, we resumed GEM plus nab-PTX. The patient has survived without any recurrence for 3 years after the initial surgery.
  • ||||||||||  Journal:  Resection of Multiple Metastases after Liver Resection from Colon Cancer-A Case Report (Pubmed Central) -  Feb 4, 2023   
    She received FOLFOXIRI therapy...Then, peritoneal dissemination resection and sigmoid colectomy were performed, and then lung resection was performed to perform R0 resection. R0 resection and multimodal therapy for simultaneous and heterotopic metastases of colorectal cancer can contribute to provide a long-term prognosis.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal, Metastases:  The Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer (Pubmed Central) -  Feb 4, 2023   
    We also used bevacizumab in 31 and panitumumab in 7 patients...Three- and five-year overall survival rate of 25 patients without distant metastasis were 79.6% and 74.9%, respectively; and 13 with distant metastasis were 61.6% and 52.6%, respectively. The efficacy, safety and postoperative outcomes of NAC for LARC are favorable, and we think that NAC will be one of the treatments for LARC.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  A Case of Multiple Lung Metastases of Pancreatic Cancer with 50 Months Survival by Sequential Chemotherapy (Pubmed Central) -  Feb 4, 2023   
    Thereafter, she was treated with gemcitabine(GEM)alone, GEM plus nab-paclitaxel(GnP), nal-CPT-11 plus 5-FU plus Leucovorin, and FOLFIRINOX for 48 months sequentially...The disease progressed rapidly and resulted in her death 50 months after relapse. The results suggest that chemotherapy may have contributed significantly to disease control in this case.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal, Metastases:  Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Non-Metastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. (Pubmed Central) -  Feb 3, 2023   
    Among 254 patients with non-metastatic PDAC initiated on FOLFIRINOX, of whom 52% were locally advanced, a total of 199 (78.3%) were explored, 142 (71.4%) underwent successful resection, and 129 (90.8%) were resected with negative margins. Despite 109 (42.9)% of patients experiencing significant toxicity, most patients could be managed through treatment-related complications to complete planned neoadjuvant chemotherapy and undergo planned surgical exploration.